Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity of Vemurafenib in combination with
Fotemustine in Patients with unresectable Stage IV melanoma harboring V600 BRAF mutation who
recurred while in treatment with Vemurafenib. In addition the feasibility and safety profile
of prolonging treatment of this drugs combination will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Paola Queirolo
Collaborator:
Istituto Nazionale per lo Studio e la Cura dei Tumori